Cartesian Therapeutics annual return on equity
2017
2018
2019
2021
2022
Cartesian Therapeutics Return on Equity (ROE) Growth & History (RNAC)
Cartesian Therapeutics's return on equity was 60.82% for fiscal 2022.
View full Cartesian Therapeutics company overviewCartesian Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | 60.82% | +1198.67 pp |
| 2021 | 2021-12-31 | −1,137.85% | — |
| 2019 | 2019-12-31 | −3,716.01% | −3434.37 pp |
| 2018 | 2018-12-31 | −281.64% | −159.29 pp |
| 2017 | 2017-12-31 | −122.36% | — |
Cartesian Therapeutics quarterly return on equity
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q4.19
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2023 | 2023-09-30 | −14.31% | −5.27 pp |
| Q2 2023 | 2023-06-30 | −16.26% | −28.10 pp |
| Q1 2023 | 2023-03-31 | −25.73% | −99.25 pp |
| Q4 2022 | 2022-12-31 | 6.59% | −639.26 pp |
| Q3 2022 | 2022-09-30 | −9.05% | — |
| Q2 2022 | 2022-06-30 | 11.83% | — |
| Q1 2022 | 2022-03-31 | 73.52% | — |
| Q4 2021 | 2021-12-31 | 645.86% | — |
| Q4 2019 | 2019-12-31 | −855.14% | +621.77 pp |
| Q2 2019 | 2019-06-30 | −220.42% | −158.44 pp |
| Q1 2019 | 2019-03-31 | −256.87% | −221.87 pp |
| Q4 2018 | 2018-12-31 | −1,476.92% | −1443.48 pp |
| Q3 2018 | 2018-09-30 | −110.10% | −89.61 pp |
| Q2 2018 | 2018-06-30 | −61.99% | −35.21 pp |
| Q1 2018 | 2018-03-31 | −35.00% | −3.48 pp |
| Q4 2017 | 2017-12-31 | −33.44% | −10.05 pp |
| Q3 2017 | 2017-09-30 | −20.49% | −8.97 pp |
| Q2 2017 | 2017-06-30 | −26.77% | — |
| Q1 2017 | 2017-03-31 | −31.51% | — |
| Q4 2016 | 2016-12-31 | −23.39% | — |
| Q3 2016 | 2016-09-30 | −11.52% | — |
Cartesian Therapeutics return on equity trends
Over the last five fiscal years, Cartesian Therapeutics's return on equity increased from −122.36% to 60.82%, a change of +183.17 percentage points. The latest reported quarter, Q3 2023, shows −14.31%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cartesian Therapeutics source filings ↗